By Chris Wack


HCW Biologics Inc. shares doubled to $6.43 Thursday after the company said it was cleared by the U.S. Food and Drug Administration to proceed to evaluate its lead drug candidate, HCW9218, in a first-in-human Phase 1b clinical trial in patients with advanced pancreatic cancer.

Volume for the stock was 124 million shares at 12:45 p.m. ET, compared with 65-day average volume of 153,000 shares. The stock hit its 52-week low of $2.36 on Oct. 22. HCW has a public float of 12.4 million shares.

The biopharmaceutical company said its HCW9218 is an injectable, fusion protein complex designed to drive bifunctional, anti-tumor activity by activating desired immune responses to attack cancer cells while simultaneously blocking unwanted immunosuppressive activities.

HCW said that preclinical studies showed that HCW9218 enhanced the anti-tumor efficacy of chemotherapy docetaxel and gemcitabine plus nab-paclitaxel against melanoma and pancreatic cancer, respectively, and simultaneously alleviated the off-target, unwanted effects of chemotherapies on normal tissues.

In experimental animal models, HCW9218 was also shown to augment anti-tumor activities of therapeutic and checkpoint antibodies, which are currently standard-of-care anti-cancer treatment for certain solid tumors, the company said.


Write to Chris Wack at


(END) Dow Jones Newswires

October 28, 2021 13:07 ET (17:07 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more HCW Biologics Charts.
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more HCW Biologics Charts.